TrialThe Journal of allergy and clinical immunology2022

Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis.

Marcus Maurer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.